The target of this trial is to evaluate the safety, tolerability and preliminary efficacy of NCR101 in the treatment of subjects with interstitial lung disease. The trial contains Single ascending dose（SAD） and Multiple ascending dose（MAD）. Subjects will receive at least 1 dose of NCR101.
Age>18 years old (including threshold), gender not limited;
Meets the diagnosis of interstitial lung disease;
Screening for interstitial lung disease diagnosed by pulmonary imaging within the first 6 months;
For patients undergoing glucocorticoid therapy at the time of screening: the background treatment remained stable during the study period;
Individuals with a history of severe allergies or allergies to the main active ingredients or excipients of the investigational drug;
Individuals who have been hospitalized for three or more times due to acute exacerbation of ILD or other respiratory diseases within the previous year prior to screening;
Individuals with a history of mechanical ventilation (invasive or non-invasive) within the past month prior to screening, or those currently requiring oxygen therapy (oxygen therapy duration>15 hours/day);
Individuals who have contracted infectious pneumonia or require intravenous anti-infective treatment within the previous month; Previous history of tuberculosis